• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Study: Stents no better than pills for some heart patients | MassDevice.com On Call

Study: Stents no better than pills for some heart patients | MassDevice.com On Call

February 28, 2012 By MassDevice staff

Updated: March 15, 2012 9:30 a.m.

MassDevice On Call

MASSDEVICE ON CALL — Stable heart disease patients were no better off with a stent with less-costly drug therapy in a recent study comparing the 2 treatments. *

Implanting a stent to prop open blocked arteries represents a more costly alternative that failed to improve outcomes in stable patients, according to researchers from the Stony Brook University Medical Center in New York.

"There was no benefit of stenting as far as reducing death, heart attack, repeat procedures and even reducing symptomatic angina," investigator Dr. David Brown told Today Online.

House Dems. call for more oversight of medical devices

House Democrats introduced a bill this month granting the FDA the power to reject devices with designs that predicate from products that were recalled, Bloomberg reported.

Supreme Court keeps Kagan amid calls for recusal

The Supreme Court again denied calls for recusal of Justice Elena Kagan in the legal challenge against President Barack Obama’s health care laws, Law360.com (paid) reported.

FDA grants Jarvik Heart trials of destination therapy

Jarvik Heart won FDA approval to begin clinical trials of its Jarvik 2000 intraventricular heart assist device as a destination therapy for patients who are not candidates for heart transplant, according to a press release.

U.S. and European governments put the squeeze on bribes paid by companies overseas

The U.S. Foreign Corrupt Practices Act and the U.K.’s Bribery Act represent renewed vigor among governments to keep an eye on and put a stop to improper payments drug and device companies might make overseas, according to a Reuters special report.

*Correction, March 15, 2012: This article originally referred to the study’s patient population as heart attack patients, rather than stable heart disease patients.

Filed Under: Healthcare Reform, Legal News, News Well, Research & Development, Stents, Structural Heart Tagged With: Jarvik Heart, U.S. Congress

More recent news

  • Neuralink files to raise $649M in new equity offering
  • BofA: Surgical robot remanufacturing not a major setback for Intuitive
  • InspireMD wins CE Mark approval for CGuard Prime
  • Philips reports first cases for VeriSight Pro 3D ICE catheter in Europe
  • Ceryx Medical raises $15M to support bioelectronic pacemaker

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy